In hematopoietic stem and progenitor cells (HSPCs) of myelodysplastic syndromes (MDS), TLR-TRAF6 signaling drives a switch in NF-κB signaling from the canonical to the non-canonical pathway by activating the A20 protein. Here, TRAF6 is linked to myelodysplastic syndrome.